Gemini Space Station Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Gemini Space Station Inc trades at $3.84 (market cap $531.57M), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 16.7× Gemini Space Station Inc's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 15 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| GEMI | KYMR | |
|---|---|---|
Market Cap | $531.57M | $8.87B |
Volume | 1,676,380 | 779,107 |
Sector | Financials | Health |
52-Week High | $22.36 | $127.31 |
52-Week Low | $3.54 | $55.80 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $510.60M | $8.26B |
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.10, down 0.24% with bearish technical signals despite recent price surges. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings estimates with a net loss of -$517 million. Analyst consensus shows mixed sentiment with a $5.25 price target, while technical indicators show oversold conditions with RSI at 10.68.
The stock faces significant fundamental challenges with negative profit margins and cash burn, though revenue diversification shows promise. Near-term catalysts include SEC regulatory developments for tokenized stocks, but legal risks and persistent losses create substantial downside potential for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →